Kenneth Lebow
Corneal and Contact Management · Virginia Beach, VANPI 1902892599
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Alcon at 32.0% of the total. Reporting peaked in 2019 at $3,357 and has fallen 88.5% since, to $387 in 2025. Among corneal and contact management clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 86 payments — averaging $75.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Johnson & Johnson Surgical Vision, Inc.$1K
- Bausch & Lomb Americas Inc.$493
- Sun Pharmaceutical Industries Inc.$393
- Johnson & Johnson Vision Care, Inc.$348
- AbbVie$275
- plus $2K from 16 others
What the payments were for
- Consulting fees$1,36521%
- Travel & lodging$1,19918%
- Food & beverage$3,89160%
- Gifts$190%
- Entertainment$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 21 | $2,078 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $1,149 |
| Bausch & Lomb Americas Inc. | 6 | $493 |
| Sun Pharmaceutical Industries Inc. | 8 | $393 |
| Johnson & Johnson Vision Care, Inc. | 6 | $348 |
| AbbVie(2 entities) | 6 | $275 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $250 |
| Mallinckrodt Hospital Products Inc. | 4 | $196 |
| Biotissue Holdings Inc. | 3 | $193 |
| Coopervision Inc. | 3 | $160 |
| Novartis | 4 | $156 |
| Aerie Pharmaceuticals, Inc. | 3 | $140 |
| Harrow Eye, LLC | 2 | $139 |
| Glaukos Corporation | 1 | $123 |
| Astellas Pharma US Inc | 1 | $121 |
| Tarsus Pharmaceuticals, Inc. | 1 | $109 |
| Oyster Point Pharma, Inc. | 2 | $44 |
| Shire North American Group Inc | 2 | $35 |
| Dompe US, Inc. | 1 | $31 |
| Kala Pharmaceuticals, Inc. | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Optos, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAILIES$1,600
- TearScience Lipiflow System$963
- TearScience Lipiview System$963
- TearScience Lipiscan System$963
- Acuvue$226
- MIEBO$226
- ACTHAR$135
- VEVYE$123
- KXL System$123
- Photrexa$123
- VYZULTA$123
- Izervay$121
- Multiple Brands Contact Lens$120
- ULTRA$118
- BTOD$118
- XIIDRA$114
- CEQUA$112
- INFUSE$111
- Rhopressa$110
- Rocklatan$110
How this compares
$6,491 in reported general payments places this provider in the 95th percentile of 24 corneal and contact management providers in Virginia.
See all corneal and contact management providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 18 | $22,703 |
| LumiganBimatoprost | 28 | $13,628 |
| RocklatanNetarsudil Mesylat/Latanoprost | 30 | $11,090 |
| Cyclosporine | 17 | $7,256 |
| Loteprednol Etabonate | 14 | $4,367 |
| Travoprost | 14 | $2,227 |
| Brimonidine Tartrate | 21 | $1,198 |
| Brinzolamide | 11 | $1,156 |
| Latanoprost | 11 | $162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $275 | $36,33146 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $140 | $11,09030 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $250 | $4,36714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 24 corneal and contact management providers in Virginia.
Other corneal and contact management in Virginia Beach
- David GilbertVirginia Beach$1K
- Garry ShoemakerVirginia Beach$697
- David RoseManassas$18K
- Courtney ThelenAnnandale$6K
- Mark MacmillanRichmond$6K
- George ButterworthMartinsville$5K
- Amanda MartinNorfolk$4K
- Miles PressLocust Grove$3K
- Frank VillaLynchburg$3K
- Richard JablonskiWoodbridge$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.